French Sanofi-Aventis Group Factory Inspection-Introduction

The birth of Sanofi-Aventis Group: With the successful acquisition of Aventis by Sanofi-Synthelabo, Sanofi-Aventis Group was born on August 20, 2004. Both companies have operations in China.

French sanofi-aventis is the largest pharmaceutical company in Europe and the third largest in the world. It was established in 2004 by the merger of Sanofi-Synthelabo and Aventis. Headquartered in Paris, it has branches in more than 80 countries, with more than 100,000 employees and a turnover of more than 25 billion euros in 2004. In Taiwan, sanofi-aventis is the second largest pharmaceutical company with a total of 320 employees. In China, Sanofi-Aventis is now ranked seventh with a market share of 1.7%. Sanofi-Aventis has been working hard to create an atmosphere of harmony, openness, fair competition and mutual respect.

Sanofi-Aventis Group is the world's third largest pharmaceutical company and the largest in Europe. Its business covers more than 100 countries around the world, and it currently has about 11,000 scientists and 100,000 employees serving the health industry.

With a world-class R&D organization developing innovative treatments, sanofi-aventis is a leader in seven therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine and vaccines.

Main business scope

The joint venture's main products are used in therapeutic areas such as cardiovascular, thrombotic, central nervous system, anti-tumor and internal medicine.

Sanofi Synthelabo has successfully introduced various advanced drugs into the Chinese market, such as Cordarone, Ticlid, Subilin, Depakine, Ambroxol, Plavix, Lexadin, etc.